Polycythemia Vera's New Market Hasn't Opened Yet. Silence Therapeutics Is About to Test Its Claim.

The market still treats Silence Therapeutics as a Phase 2 biotech burn rate. That was the right story six months ago. The SANRECO trial readout is days away, the competitive landscape has shifted in ways that haven't settled, and the stock's recent ten-percent slide looks more like pre-catalyst jitters than a business problem. The question isn't whether polycythemia vera is a worth-paying-attention market. It's whether divesiran's data is going to be good enough to command a seat at a table that's about to expand dramatically.

The old story

PV is a rare blood cancer that causes the body to overproduce red blood cells. The standard of care is phlebotomy — literally draining blood from patients on a recurring schedule — combined with hydroxyurea for those who can tolerate it. About a quarter of patients develop resistance or can't handle hydroxyurea at all. Beyond that, Jakafi (ruxolitinib), a JAK inhibitor approved for second-line PV since 2014, has generated roughly $965 million in annual revenue as the only real blockbuster in the space.

The treatment landscape was thin until it wasn't. In January 2026, Takeda and Protagonist Therapeutics filed an NDA for rusfertide, a first-in-class hepcidin mimetic peptide that regulates iron homeostasis to control red blood cell production. Its Phase 3 VERIFY study met the primary endpoint and all four key secondary endpoints in 293 phlebotomy-dependent patients. FDA approval is expected in Q4 2026. Rusfertide would be the first hepcidin-targeting therapy on the market, administered as a once-weekly subcutaneous injection.

The market this is opening into matters. PV is valued at roughly $1.9 billion today in the seven major markets and is projected to grow to $5.3 billion by 2034, at a CAGR of 10.8%. The U.S. alone has approximately 180,000 prevalent cases. The treatment category is moving from a phlebotomy-and-hydroxyurea era to a targeted-mechanism era, and the first approved hepcidin drug is going to define the standard.

The new evidence

Divesiran targets the same pathway as rusfertide but through a different mechanism. It's a short interfering RNA — an siRNA therapeutic that silences the TMPRSS6 protein in liver cells. TMPRSS6 normally inhibits hepcidin. Divesiran removes that brake, raising hepcidin levels, redirecting iron delivery away from the bone marrow, and lowering red blood cell production. Same destination, different vehicle.

Phase 1/2 data presented at ASH and published in Blood was striking. Nineteen patients with an average baseline hematocrit of 47% received divesiran every six weeks. Before treatment, they accumulated 79 phlebotomies over six months. After treatment, patients with baseline hematocrit below 50% required zero phlebotomies. Four patients with baseline hematocrit above 50% collectively needed only six total phlebotomies. No dose-limiting toxicities. No serious treatment-related adverse events. No discontinuations. Eighty-one percent of treatment-emergent adverse events were Grade 1.

The SANRECO Phase 2 trial — the one releasing topline results in the coming days — is a global, randomized, double-blind study of 48 phlebotomy-dependent PV patients comparing divesiran to placebo. The primary endpoint measures the proportion of patients maintaining hematocrit below 45% between weeks 18 and 36 without phlebotomies. It evaluates both every-6-week and every-12-week dosing.

The dosing intervals are the competitive question. If the Q12W arm holds up, divesiran could offer four annual doses versus rusfertide's 52. That's a material convenience advantage in a chronic condition where treatment adherence and quality of life drive long-term adherence. Even Q6W (eight annual doses) is a significant step away from weekly injection. The SANRECO readout will tell whether the longer interval is viable.

The cash-flow reality

Silence held $70.1 million in cash and short-term investments as of March 31, 2026. General and administrative expenses fell to $22.3 million in 2025, down from $26.9 million the prior year. The company has been cutting costs, but it's still burning roughly $55 to $60 million annually, and there's no revenue. At that burn rate, the cash runway extends into 2027 — enough to get through the SANRECO readout, but not enough to wait around for what comes next.

That's the structural urgency. The company needs SANRECO to open a door — a partnership, a co-development deal, or acquisition interest. There's no path to profitability without one. The $70 million bridge runs out before a standalone PV approval would generate sales.

Why the market is still misreading this

The recent selloff — roughly 10% in a single session as the readout date approached — reads as binary-event anxiety, not fundamental deterioration. Investors see rusfertide arriving in Q4 2026 and assume first-mover advantage locks up the market. They see a Phase 2 readout and price it as a speculative binary. They see a cash-burning company with no revenue and apply the small-biotech discount.

The counter-point is that hepcidin isn't going to be a single-winner market. Rusfertide's mechanism is a weekly injection. If divesiran's longer dosing interval holds up in SANRECO, it addresses the two practical limitations of any injectable chronic therapy: frequency and burden. The PV market is about to triple in size over the next decade. A second hepcidin developer with a differentiated dosing profile isn't a loser; it's a partner. And in a rare-disease market where the addressable population is narrow and the mechanism is proven, partners get acquired.

The financial bridge

Here's what needs to happen for the inflection to work:

SANRECO meets its primary endpoint, showing divesiran maintains hematocrit below 45% without phlebotomies in a substantial proportion of the 48-patient cohort. The Q12W dosing arm shows sufficient efficacy to support a differentiated value proposition versus weekly injection. It doesn't need to match Q6W — it needs to be credible enough to justify the interval in a partnership discussion. A partner materializes within 12 months. The hepcidin PV space is attracting attention: Takeda/Protagonist are committed at scale, and other pipeline players (Italfarmaco's givinostat, Vanda's VGT-1849B, Ionis's sapablursen) are racing toward clinical milestones. Silence's siRNA platform extends beyond PV, which adds option value.

If SANRECO is positive and the dosing story lands, a mid-to-high $100 million partnership or acquisition isn't out of reach. Silence trades at roughly $10 per share, implying a market cap around $300 million. A $200-to-$400 million all-in deal would represent a meaningful step-up, assuming the data supports it.

The tripwire

If SANRECO fails to meet its primary endpoint — if hematocrit control isn't materially better than placebo — the thesis breaks. There's no second Phase 2 in the budget. No pivot that justifies the burn. Discipline over ego.

Even if the primary endpoint is met, a Q12W arm that shows no meaningful signal versus Q6W narrows the competitive story. Divesiran would still be a candidate, but the dosing advantage — the one thing that differentiates it from rusfertide — would be gone. The company would still need a partner, but at a lower valuation.

The setup

This isn't a stock you hold passively. The SANRECO readout is the gate. If the data is clean — primary endpoint met, Q12W credible, safety holding — the rerating from "burning cash with no path" to "proven mechanism with partnership optionality" could move the stock quickly. If it misses, cut it. The cash runway doesn't support a wait-and-see approach.

The market is pricing Silence for a miss. That's the entry condition. The question over the next 48 hours is whether the data validates the mechanism well enough to make the old story obsolete.